Arthripain Relief

Description

ArthriPain is presented in packaging that includes a display panel. The design of the packaging is intended to provide essential product information and facilitate visibility for healthcare professionals and patients.

Uses and Indications

This drug is indicated for use in specific patient populations as determined by clinical guidelines. Healthcare professionals should refer to the prescribing information for detailed indications and usage recommendations.

Limitations of use and any potential teratogenic or nonteratogenic effects have not been specified in the provided information. It is essential for healthcare providers to evaluate the appropriateness of this drug based on individual patient circumstances and existing clinical data.

Dosage and Administration

For adults and children aged 2 years and older, the recommended application is to the affected area not more than 3 to 4 times daily. It is important to ensure that the application is limited to the specified frequency to avoid potential adverse effects.

For children under 2 years of age, it is advised to consult a physician prior to use to determine the appropriate course of action and ensure safety.

Contraindications

The product is contraindicated for use on wounds or damaged skin due to the potential for adverse effects and impaired healing. No other contraindications have been specified.

Warnings and Precautions

The product is contraindicated for use on wounds or damaged skin. Healthcare professionals should advise patients to discontinue use and consult a physician if the condition worsens or if symptoms persist for more than 7 days. Additionally, if symptoms resolve and then recur within a few days, patients should also seek medical advice.

While using this product, it is imperative to avoid contact with the eyes and mucous membranes to prevent irritation or adverse reactions. Furthermore, patients should be instructed not to apply tight bandages over the treated area, as this may exacerbate potential side effects or hinder the product's effectiveness.

Emergency medical assistance should be sought if any severe reactions occur, although specific instructions for such situations are not provided in the current guidelines.

No laboratory tests are recommended for monitoring during the use of this product.

Side Effects

Patients should discontinue use and consult a healthcare professional if their condition worsens or if symptoms persist for more than 7 days. Additionally, if symptoms resolve and then recur within a few days, it is advised to seek medical advice.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Arthripain Relief (menthol). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 2 years and older may apply the medication to the affected area no more than 3 to 4 times daily. For children under 2 years of age, it is advised to consult a physician prior to use. Additionally, it is important to keep the product out of reach of children to ensure safety.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is no specific information regarding the use of ARTHRIPAIN RELIEF - menthol cream during pregnancy. The prescribing information does not provide safety concerns, dosage modifications, or special precautions for pregnant patients. Therefore, healthcare professionals should exercise caution when recommending this product to women of childbearing potential and consider the lack of data on potential fetal impacts. It is advisable to weigh the benefits against any unknown risks when considering the use of this product in pregnant patients.

Lactation

There are no specific warnings or recommendations regarding the use of this product by lactating mothers. Additionally, there are no known concerns related to the potential for excretion in breast milk or associated risks for breastfed infants.

Renal Impairment

There is no specific information regarding renal impairment, dosage adjustments, special monitoring, or safety considerations for patients with reduced kidney function provided in the drug insert for ARTHRIPAIN RELIEF - menthol cream. Healthcare professionals should exercise caution and consider the lack of data when prescribing this product to patients with renal impairment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to ARTHRIPAIN RELIEF - menthol cream. The prescribing information does not provide any recommendations regarding dosage adjustments, special monitoring, or precautions for individuals with compromised liver function. Therefore, healthcare professionals should exercise caution and consider the overall clinical context when prescribing this medication to patients with hepatic impairment.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to contact a poison control center or consult relevant clinical guidelines for further management strategies tailored to the specific circumstances of the overdose.

Documentation of the incident, including the substance involved, the amount ingested, and the time of ingestion, is crucial for effective treatment and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children to prevent accidental ingestion or misuse. Patients should be instructed not to apply the product on wounds or damaged skin, as this may lead to adverse effects.

Patients must be informed to discontinue use and consult a doctor if their condition worsens or if symptoms persist for more than 7 days. Additionally, they should be cautioned to stop using the product and seek medical advice if symptoms improve and then recur within a few days.

While using the product, patients should be reminded to avoid contact with the eyes and mucous membranes to prevent irritation. Furthermore, it is important to advise patients not to bandage the area tightly when using the product, as this may affect its efficacy and safety.

Storage and Handling

The product is supplied in a tube format, with specific handling and storage requirements to ensure its integrity and efficacy. It should be stored at room temperature, away from direct light exposure. To maintain the quality of the product, it is essential to keep the tube tightly closed when not in use. Additionally, the product should be discarded after opening to prevent any potential degradation or contamination.

Additional Clinical Information

The medication is administered topically, with the recommended application frequency for adults and children aged 2 years and older being 3 to 4 times daily to the affected area. For children under 2 years of age, it is advised to consult a physician prior to use. No further information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Arthripain Relief, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)